Effectiveness of Interdisciplinary vs. Dermatological Care of Moderate- to-severe Psoriasis: A Pragmatic Randomised Controlled Trial

Schmitt, Jochen; Wozel, Gottfried; Garzarolli, Marlene; Viehweg, Antje; Bauer, Michael; Leopold, Karolina

doi:10.2340/00015555-1697

Cited by 15 publications

(10 citation statements)

References 35 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Limited evidence from small randomized trials suggests the effectiveness of interdisciplinary care involving psychiatric support on the quality of life of patients with psoriasis . Giving the bearing of psychiatric comorbidities on quality of life and their impact on disease management, patients with psychological distress or symptoms of depression should be offered referral to a psychiatrist and psychological support.…”

Section: Resultsmentioning

confidence: 99%

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Gisondi

Altomare

Ayala

et al. 2017

Acad Dermatol Venereol

150

View full text Add to dashboard Cite

Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.

show abstract

Section: Resultsmentioning

confidence: 99%

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Gisondi

Altomare

Ayala

et al. 2017

Acad Dermatol Venereol

150

View full text Add to dashboard Cite

show abstract

“…Limited evidence from small randomized trials suggests the effectiveness of interdisciplinary care involving psychiatric support on the quality of life of psoriatic patients [ 24 ]. Given the bearing of psychiatric comorbidities on quality of life and their impact on disease management, patients with psychological distress or symptoms of depression should be offered referrals to a psychiatrist and psychological support.…”

Section: Non-pharmacological Treatment Approachesmentioning

confidence: 99%

Treatment Approaches to Moderate to Severe Psoriasis

Gisondi

Giglio

Girolomoni

2017

IJMS

View full text Add to dashboard Cite

Psoriasis is a common disease, which has a considerable impact on patients and the health care system. Treatment approaches to the disease may be various because some issues are not definitely addressed. Moreover, the therapeutic paradigms are continuously changing because of the recent approval of new treatments for psoriasis such as interleukin (IL)-17 inhibitors and apremilast. In this review, the factors influencing psoriasis severity, the indications for systemic treatments, the overall parameters to be considered in the treatment choice, life style interventions, and the recommendations for the use, screening, and monitoring of systemic therapies available including acitretin, cyclosporine, methotrexate, apremilast, adalimumab, etanercept, infliximab, secukinumab, ixekizumab, and ustekinumab are discussed. Finally, treatment approaches in special patient populations including children, the elderly, pregnant women, patients with a history of neoplasm, and candidates for surgical procedures are reported.

show abstract

“…The appearance and lifelong, chronic nature of psoriasis result in considerable burden to patients, such as sleep impairment, depressive symptoms, negative self‐esteem and reduced work productivity . Assessment of psoriasis severity and response to treatment in clinical trials is typically made using the Psoriasis Area and Severity Index (PASI) .…”

mentioning

confidence: 99%

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

Effectiveness of Interdisciplinary vs. Dermatological Care of Moderate- to-severe Psoriasis: A Pragmatic Randomised Controlled Trial

Cited by 15 publications

References 35 publications

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Treatment Approaches to Moderate to Severe Psoriasis

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

Contact Info

Product

Resources

About